B
CRVS icon

Bailard’s Corvus Pharmaceuticals CRVS Stock Holding History

Bailard’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-39,998
Closed -$33K – 720
2022
Q3 		$33K Buy
+39,998
New +$38.2K ﹤0.01% 654

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bailard's CRVS Position: Q4 2022 in Review

Bailard sold out of Corvus Pharmaceuticals (CRVS) in Q4 2022, closing a stake of 39,998 shares — an estimated $33K sold.

Bailard first reported a position in CRVS in Q3 2022 and held it in 1 quarter. The position peaked at $33K in Q3 2022. 41 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

  • Bailard reported no remaining Corvus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Bailard sold 39,998 Corvus Pharmaceuticals shares in Q4 2022, an estimated $33K.
  • Bailard first reported a position in Corvus Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Bailard's Corvus Pharmaceuticals position peaked at $33K in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.